Edwards Lifesciences Corp [EW] stock is trading at $80.47, up 2.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EW shares have gain 5.47% over the last week, with a monthly amount glided 2.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on July 29, 2025, when BTIG Research upgraded its rating to a Buy but kept the price target unchanged to $100 for it. Previously, Piper Sandler upgraded its rating to Overweight on April 24, 2025, and kept the price target unchanged to $80. On January 30, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $90 on the stock. Wolfe Research downgraded its rating to a Underperform but stick to its price target of $60 on January 16, 2025. BofA Securities upgraded its rating to a Buy. In a note dated September 18, 2024, Jefferies downgraded an Hold rating on this stock and revised its target price from $85 to $70.
Edwards Lifesciences Corp [EW] stock has fluctuated between $59.41 and $83.00 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $80.47 at the most recent close of the market. An investor can expect a potential drop of -6.8% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 5.69B for the trailing twelve months, which represents a growth of 10.56%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.73%. To continue investigating profitability, this company’s Return on Assets is posted at 0.32, Equity is 0.45 and Total Capital is 0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 79.54 points at the first support level, and at 78.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 80.96, and for the 2nd resistance point, it is at 81.46.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 4.45. As well, the Quick Ratio is 3.66, while the Cash Ratio is 2.25. Considering the valuation of this stock, the price to sales ratio is 8.30, the price to book ratio is 4.66 and price to earnings (TTM) ratio is 55.22.
Transactions by insiders
Recent insider trading involved Lippis Daniel J., CVP, JAPAC, that happened on Jul 28 ’25 when 4114.0 shares were sold. Officer, Lippis Daniel J. completed a deal on Jul 28 ’25 to buy 4114.0 shares. Meanwhile, Global President TAVR & Surg Wood Larry L sold 8950.0 shares on Jun 16 ’25.
